Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 852 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx se xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 o xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx a xxxxx

(Xxxx x xxxxxxxx xxx EHP)

EVROPSKÁ XXXXXX,

x xxxxxxx xx Smlouvu x fungování Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x změně x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx nařízení (XX) x. 1907/2006 (1), x xxxxxxx na xx. 37 xxxx. 5 xxxxxxxxx nařízení,

vzhledem x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx nebezpečných xxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxxx x částech 2 až 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x xxxxxxx x článkem 37 xxxxxxxx (ES) x. 1272/2008 předloženy návrhy xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx a xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Na základě xxxxxxxxxx&xxxx;(2) k těmto xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx zavést, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru RAC xxxx:

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx vláken x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx granulované xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx bis (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx dioktyltin-dilaurátu, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. ledna 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (ISO), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně L-(+)-mléčné xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx x natria-N-(hydroxymethyl)glycinátu],

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, mecetronium-ethyl-sulfátu [XXX],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanonu,

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 ohledně 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, penflufenu,

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx za studena xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx fosfinu,

—

stanovisko ze xxx 14. xxxx 2018 xxxxxxx dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně olova,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx okthilinonu (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx imiprothrinu (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (xxxxx XXX 7439–92–1 x indexová xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), XXX ve xxxx stanovisku ze xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx celistvou i xxxxxxxxx formu. Avšak xxxxxxxx k xxxxx xxxxxxxxx xxxxxxxxxxx celistvé xxxxx, tvárné xxxxxxxxx xxxxx, ke specifické xxxxxxx výrobě prášku x xxxxxxxx x xxxxx environmentální klasifikaci x celistvých x xxxxxxxxxx xxxxx xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx x příloze XX musí XXX xxxxxxx xxxxx xxxxxxxxx xxxx, zda xx xxx xx celistvou x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, x xxxxx xxxxxxx, xx environmentální xxxxxxxxxxx xxx celistvou formu, xxx xx xxxxxxxxxx xxxxxxxxxx výboru RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx xxxxx xxxxx xxxxxx zařazena xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx RAC nebude xxx xxxxxxx xxxxxxxxx xxxxxxxxxx stanovisko.

(4)

Pokud xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), pro xxxxx xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx předloženy xxxx xxxxxxx xxxxxxxx, xx kterých xxxxxxx, xx xxxxxxxxxxx xxx xxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx RAC, jež xx xxxxxxx xx xxxxxxxx údajích, xxxxxx xxx xxxxxx. Tato xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x příloze VI xxxxxxxx (XX) x. 1272/2008 xxxxxxx, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx k xxxxx novým xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx pojednává xxxxxxxxxx xxxxxx XXX, xx zařazeny xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx by xxxxxx xxx, x výhradou xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx to, xxx xxxxxxxxxxxx označování x xxxxxx látek x xxxxx xxxxx xxxx revidovaným xxxxxxxxxxxx x prodali xxxxxxxxx xxxxxx. Xxxx xxxx xx xxxxxx nezbytná x tomu, xxx xxxxxxxxxx měli dostatek xxxx xxxxxxxx xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx xxxxxxxxx, které xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx zahrnovat xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 písm. f) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (ES) x. 1907/2006&xxxx;(3) nebo xxxxxxxxx xxxxxxxxx v xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx xxx umožněno, xxx xxxxx nová xxxxxxxxxx týkající xx xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. Xx xx v souladu x xxxxxxxxx xxxxx xx. 61 xxxx. 2 nařízení (XX) x. 1272/2008,

PŘIJALA TOTO XXXXXXXX:

Článek 1

Xxxxx nařízení (XX) x. 1272/2008

Tabulka 3 v xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx xxxx x xxxxxxx s xxxxxxxx tohoto xxxxxxxx.

Článek 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx xx ode xxx 1. xxxxxx 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x směsi xxxxxxxxxxxxx, xxxxxxxxxx a baleny x souladu x xxxxxxxxx (XX) x. 1272/2008 ve znění xxxxxx xxxxxxxx xxxxx xxxxx dnem 1. xxxxxx 2022.

Xxxx nařízení xx xxxxxxx x xxxxx xxxxxxx x přímo xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Xxxxxx

Xxxxxx VON XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. věst. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx stránce: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x omezování chemických xxxxx, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x zrušení xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x směrnic Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x xxxxxxxx biocidních xxxxxxxxx na xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xx xxxxxxx 3 x xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx a XXX

Xxxxxxxx

Xxxx tříd x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx vět x nebezpečnosti

„007-030-00-3

kyselina dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 A; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x karbidu xxxxxxx (x xxxxxxx &xx; 3 μm, xxxxx &xx; 5 μx x s xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„016-098-00-3

dimethyl-disulfid

210-871-0

624-92-0

Flam. Liq. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

STOT SE 3

XXXX SE 1

Xxx Xxxxx. 2

Skin Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx dýchací cesty, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (páry)

orální: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: od 0,9 xx x xx 6,0 xx; xxxxx xxxxxx: xx 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

H411

GHS09

H411“

„029-025-00-5

bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď;

bis(N-cyklohexyl-diazenium-dioxy)-měď;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Xxx. 1

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (játra)

H318

H410

orální: ATE = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

Aquatic Chronic 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Acute Xxx. 4

Acute Xxx. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 mg/l (prach xxxx xxxx)

xxxxxx: XXX = 490 mg/kg XX

X = 10

X = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1B

Muta. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Sens. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX RE. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

H302

H373 (játra)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx TH

M = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

STOT RE 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 mg/kg TH

M = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

H314

H318

GHS05

Dgr

H314

EUH071“

„607-744-00-0

2-methoxyethylakrylát

221-499-3

3121-61-7

Flam. Xxx. 3

Xxxx. 2

Repr. 1B

Acute Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová xxxxxxxx …%

206-058-5

298-12-4

Xxx Dam. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX SE 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (prach xxxx xxxx)

xxxxxx: XXX = 1 100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

XXXX RE 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

XXXX XX 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: XXX = 0,14 mg/l (xxxxx xxxx mlha)

orální: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Tox. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalační: ATE = 0,16 xx/x (xxxxx xxxx mlha)

orální: XXX = 567 xx/xx XX

Xxxx Irrit. 2; H315: 0,025 % ≤ X &xx; 5 %

Eye Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; H317: X ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Acute Xxx. 3

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Xxxx. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 mg/kg XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1B

Muta. 1X

XXXX XX 1

H350

H340

H372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx ze xxxxx xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx výstražných xxxxxxx x signálních xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Acute Xxx. 1

Xxxx Corr. 1 A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Xxx. 2; H272: X ≥ 99 %

Ox. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX RE 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X302

X372 (nervový xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1 414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1B

Acute Xxx. 2

STOT XX 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 D: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx částic &xx; 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-butoxyethan-1-ol;

ethyleneglykolmonobutylether

203-905-0

111-76-2

Acute Tox. 4*

Xxxxx Tox. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 mg/kg TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Xxx Irrit. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: ATE = 300 xx/xx XX orální: XXX = 500 mg/kg XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Sens. 1

Aquatic Xxxxx 1

Aquatic Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Xxxxx Xxx. 3

Acute Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: ATE = 311 xx/xx XX xxxxxx: XXX = 125 mg/kg XX

Xxxx Xxxx. 1 A; X317: X ≥ 0,0015 %

M = 100

X = 100“

„613-115-00-1

hymexazol (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Xxx. 1

Skin Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 xx/xx TH“

„613-125-00-6

hexythiazox (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Repr. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (xxxxxxx systém; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

M = 10“

„616-014-00-0

xxxxx-xx-xxxx; ethylmethylketoxim, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Tox. 4

Acute Xxx. 3

STOT XX 3

XXXX XX 1

XXXX XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Skin Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx dýchací xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxxxxx Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.